The global fish-based pet food market is projected to reach USD 11.8 billion by 2036, rising from USD 6.2 billion in 2026, reflecting a steady CAGR of 6.7%, according to Future Market Insights (FMI). What was once considered a flavor alternative is now evolving into a clinically directed nutritional segment, driven by veterinary recommendations for pets suffering from protein sensitivities, dermatological issues, and inflammatory disorders.
Veterinarians increasingly prescribe fish-based formulations rich in EPA and DHA to manage allergies, joint conditions, and skin health. This clinical positioning is structurally elevating fish-based diets from a commodity segment to a premium therapeutic nutrition platform across global markets.
A defining industry milestone occurred in June 2025 when Mars Petcare became the first pet food manufacturer to commit to the Global Dialogue on Seafood Traceability (GDST) Standard, in partnership with Global Dialogue on Seafood Traceability and Wholechain. The initiative establishes full marine ingredient traceability across its portfolio, reinforcing sustainability and compliance transparency.
Rick Riggins, Senior Vice President at Mars Petcare, stated that adopting the GDST Standard ensures responsibly sourced and fully traceable seafood ingredients. FMI analysts anticipate GDST compliance becoming a baseline requirement within five years, similar to non-GMO and organic certifications in human food.